|
CorRestore® System Updates and News
A five-year international trial of 1,198 Surgical
Ventricular Restoration (SVR) patients provides compelling evidence
that SVR is a safe an effective treatment for certain types of CHF.
(1)
- Improved ejection fraction. Post-op ejection
fraction increased from
30% to 40%
- Left ventricular end systolic volume index
decreased from 80 ml/m2
to 57 ml/m2
- Freedom from readmission to the hospital
for CHF at five-years was 78%
- Overall five-year survival was 69%*
- Substantial improvement in NYHA functional
class. At last follow up, 89%
of the formerly predominately Class IV CHF patients were NYHA
Class I or Class II
1 Presented at the 2004 Annual Meeting of The
Society of Thoracic Surgeons.
* By Kaplan-Meier Survival Analysis
More information
about SVR with the CorRestore System is available at the CorRestore
System Products page and the
Clinical Center.
Contact
Us if you have questions or comments, need information sent
to you, or would like to be added to our e-mail distribution list
for Somanetics news and updates.
Our Customer
Service Center is always open when you need to order our products,
or have customer service or technical questions.
Request Form
for more information.
© 2001-2006
Somanetics Corporation, Troy Michigan
Legal Disclaimer
|
